Tolvaptan 15MG (jynarque)
Ended Awarded Last action
- Contract number
- 36C26223F0121
- Awardee
-
Otsuka America Pharmaceutical Inc. UEI QKABLBMA8FT9
- Awarding agency
-
Veterans Integrated Service Network 22
Veterans Health Administration, Department of Veterans Affairs
- Obligated
- $94,669
Award facts
- Contract value 100% obligated
- $94,669.12 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 325412 Pharmaceutical Preparation Manufacturing
- PSC
- 6505 Drugs And Biologicals
- Set-aside
- No set-aside
- Competition
- Full and Open Competition · 1 offer Multiple Award, Fair Opportunity
- Pricing
- Firm Fixed Price
- Place of performance
- Pittsburgh, PA 15275, USA
Award details come from SAM.gov/FPDS.
Transactions
| Action | Obligated | Date |
|---|---|---|
| Funding Only Action | -$31,013 | |
| Original award | $125,683 |
About this award
The Department of Veterans Affairs, Veterans Integrated Service Network 22, awarded a delivery order to Otsuka America Pharmaceutical Inc. for Tolvaptan 15mg (Jynarque) on December 20, 2022, with a ceiling value of $94,669.12. This firm-fixed price delivery order, which was completed by December 19, 2023, was issued without a set-aside designation and performed in Pittsburgh, Pennsylvania. Jynarque is a specialty pharmaceutical used to treat autosomal dominant polycystic kidney disease and hyponatremia in veteran populations. The delivery order was issued under the Pharmaceuticals and Drugs Federal Supply Schedule (FSS-61-IB), which serves as the parent master contract vehicle for this procurement.
Otsuka America Pharmaceutical Inc., a Maryland-headquartered for-profit pharmaceutical manufacturer, is a primary supplier of specialty pharmaceuticals to the VA's Veterans Health Administration. The company holds substantial indefinite delivery vehicles with the VA, including an $83.3 million blanket purchase agreement for Jynarque and a $396 million Federal Supply Schedule contract for pharmaceuticals and hematology products. These overarching agreements enable VA facilities across multiple Integrated Service Networks nationwide to efficiently procure critical pharmaceutical treatments for veterans, with delivery orders such as this one supporting the VA's comprehensive healthcare mission.
Quick answers
Who was awarded contract 36C26223F0121?
36C26223F0121 was awarded to Otsuka America Pharmaceutical Inc. by Veterans Integrated Service Network 22 (Veterans Health Administration) on December 20, 2022.
How much is contract 36C26223F0121 worth?
The government has obligated $94,669 on 36C26223F0121.
Is contract 36C26223F0121 an order under another contract?
Yes. 36C26223F0121 is a delivery order under 36F79720D0099, a federal supply schedule, on Pharmaceuticals and Drugs (FSS-61-IB).
Was contract 36C26223F0121 competed?
The extent of competition for 36C26223F0121 was full and open competition. The government received 1 offer.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award